Joyce A. Cramer's Lifetime Accelerator Award for Innovations in Epilepsy Treatment

Celebrating Joyce A. Cramer

In a tremendous achievement for the epilepsy community, Joyce A. Cramer has been awarded the 2026 Lifetime Accelerator Award by the Epilepsy Foundation of America. This award recognizes her exceptional contributions to the field of epilepsy treatment development throughout her distinguished career. Cramer is renowned for her innovative efforts aimed at improving epilepsy therapies and enhancing the quality of life for patients affected by this neurological disorder.

The Lifetime Accelerator Award is a notable accolade that spotlights individuals whose work has notably advanced therapy development for epilepsy. Joyce Cramer's exceptional career trajectory demonstrates her commitment to not only pioneering clinical research but also fostering innovative solutions for healthcare challenges. During her time at the Yale University School of Medicine, Cramer built a solid foundation in pre-clinical research before embarking on a successful career in leading clinical trials. Her influence was particularly significant in the 1980s, when she played a vital role in the original VA cooperative studies that established optimal therapeutic strategies for epilepsy patients.

One of Cramer's most notable legacies is her work on patient compliance with anti-seizure medications. She was a trailblazer in revealing that noncompliance is a prevalent and critical issue within epilepsy care, advocating for the integration of patient-reported outcomes into clinical research. As one of the creators of the Quality of Life in Epilepsy Inventory (QOLIE) and the Seizure Severity Questionnaire (SSQ), she provided new tools for therapy developers to assess the real-world implications of epilepsy treatments on patients’ lives.

After her impactful tenure at Yale, Cramer helmed the Epilepsy Therapy Project (ETP), where she served as President and Chief Scientific Officer. Here, she guided a myriad of entrepreneurs and pharmaceutical companies dedicated to bringing cutting-edge therapies to market. Her strategic leadership helped the ETP become a catalyst for innovation, providing crucial funding and connecting scientists, investors, and developers, thereby accelerating the translation of research into viable therapeutic options.

With over 230 peer-reviewed publications and several books to her name, Cramer's scholarly contributions have significantly shaped the field of neurology and epilepsy research. Her determination to elevate the standard of care for individuals with epilepsy has not only resulted in better treatment protocols but also a vital focus on the quality of care.

Joyce Cramer's exceptional work in elevating patient-reported outcomes and her dedication to patient welfare are the reasons she is being honored with this award.